Plant Name: Ericameria diffusa
Taxonomic Information:
Plant ID: NPO25093
Plant Latin Name: Ericameria diffusa
Taxonomy Genus: Ericameria
Taxonomy Family: Asteraceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| NPSR1; | |
| KDR; CDK1; AURKB; IGF1R; AXL; PIM1; FLT3; MET; | |
| CA12; CA7; | |
| ALOX12; NOX4; HSD17B10; HSD17B2; POLB; | |
| TYR; | |
| AHR; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.322E-07 | 3.615E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.494E-07 | 3.615E-04 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 1.409E-06 | 1.320E-03 | AXL, FLT3, IGF1R, KDR, MET |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.454E-06 | 1.320E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 1.823E-06 | 1.357E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.934E-06 | 1.357E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.934E-06 | 1.357E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 2.506E-06 | 1.517E-03 | ALOX12, CYP1A1, CYP1A2, CYP1B1, HSD17B10, HSD17B2, NOX4, TYR |
| BP | GO:0032502; developmental process | GO:0007568; aging | 4.077E-06 | 1.973E-03 | AURKB, CDK1, CYP1A1, NOX4, POLB |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.746E-06 | 2.825E-03 | CYP1A1, CYP1A2 |
| BP | GO:0050896; response to stimulus | GO:0014070; response to organic cyclic compound | 7.616E-06 | 3.071E-03 | CDK1, CYP1A1, CYP1A2, CYP1B1, FLT3, NOX4, TYR |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.009E-05 | 3.788E-03 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 2.223E-05 | 7.333E-03 | ALOX12, AURKB, AXL, CDK1, IGF1R, KDR, PIM1 |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 2.356E-05 | 7.658E-03 | FLT3, KDR |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.431E-05 | 7.785E-03 | ALOX12, CYP1A1, CYP1A2, CYP1B1 |
| CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 2.505E-05 | 7.906E-03 | AURKB, CDK1, POLB |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 3.140E-05 | 9.116E-03 | CYP1A1, CYP1A2 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 9.735E-21 | 1.704E-18 | CA12, CA1, CA3, CA2, CA5A, CA4, CA7, CA6, CA9, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 2.436E-11 | 1.421E-09 | CAMK2B, SRC, MMP2, KDR, AKT1, PIK3R1, TP53, HIF1A, MMP9, MET, PTK2, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 4.529E-10 | 1.981E-08 | GSK3B, FLT3, DAPK1, MMP2, PIK3R1, HIF1A, MMP9, NFKB1, PTK2, IGF1R, AR, AKT1, MET, TP53 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.664E-11 | 1.421E-09 | CYP2C9, CYP2C8, PLA2G1B, CYP1A2, ALOX15, CYP3A4, CYP2C19 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 9.964E-10 | 3.488E-08 | HSD17B1, ALOX5, HSD17B2, CYP1A1, CYP1B1, CYP19A1, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 4.724E-09 | 1.181E-07 | CYP2C9, CYP2C8, PLA2G1B, ALOX5, ALOX15, ALOX12, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.925E-09 | 8.531E-08 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 6.078E-08 | 1.064E-06 | GSK3B, AR, AKT1, PIK3R1, TP53, NFKB1, IGF1R |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.440E-07 | 3.762E-06 | PLA2G1B, MAOA, ALOX15, AKR1B1, ALOX12, PYGL, CYP2C19, CYP3A4, TYR, CYP19A1, HSD17B10, CYP2C9, CYP2C8, HSD17B1, ALOX5, HSD17B2, CYP1A2, CYP1A1, XDH |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 3.798E-08 | 7.384E-07 | FLT3, MMP3, TP53, MPO, MMP9, MET, NFKB1, PTK2, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.428E-08 | 7.384E-07 | CYP2C9, CYP2C8, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP2C19 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.972E-07 | 3.850E-06 | CYP2C9, CYP2C8, MAOA, ALOX5, ALOX15, ALOX12, CYP2C19 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 9.243E-07 | 1.011E-05 | GSK3B, KDR, AKT1, PIK3R1, PKN1, TP53, MET, PTK2, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.580E-07 | 3.762E-06 | FLT3, AKT1, PIK3R1, TP53, MET, HIF1A |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 3.080E-07 | 3.850E-06 | CYP2C9, CYP2C8, MAOA, CYP1A2, CYP3A4, CYP2C19 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.331E-06 | 1.294E-05 | GSK3B, SRC, KDR, AKT1, PIK3R1, MET, PTK2, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.787E-06 | 1.646E-05 | SRC, AKT1, STAT6, PIK3R1, TP53, MMP9, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 1.226E-06 | 1.262E-05 | CAMK2B, GSK3B, SRC, AKT1, PIK3R1, PTK2 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 5.670E-07 | 6.615E-06 | DAPK1, SRC, MMP2, MMP9, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 3.303E-06 | 2.752E-05 | CAMK2B, AKT1, PIK3R1, HIF1A, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 3.016E-06 | 2.639E-05 | FLT3, PIM1, AKT1, PIK3R1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 5.804E-06 | 4.232E-05 | CAMK2B, AKT1, PIK3R1, TP53, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 4.232E-06 | 3.367E-05 | SRC, KDR, AKT1, PIK3R1, PTK2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 7.262E-06 | 5.084E-05 | GSK3B, SRC, AKT1, PIK3R1, TP53, HIF1A |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 8.000E-06 | 5.385E-05 | CAMK2B, GSK3B, AKT1, PIK3R1, TP53, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 9.172E-06 | 5.732E-05 | GSK3B, CXCR1, SRC, AKT1, PIK3R1, NFKB1, PTK2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 1.514E-05 | 8.548E-05 | GSK3B, CSNK2A1, CDK1, AKT1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 8.982E-06 | 5.732E-05 | AKT1, PIK3R1, TP53, MET, IGF1R |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 5.804E-06 | 4.232E-05 | CYP2C9, CYP2C8, CYP1A2, CYP1A1, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 9.622E-06 | 5.807E-05 | GSK3B, SRC, AKT1, PIK3R1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 1.637E-05 | 8.954E-05 | GSK3B, CSNK2A1, AKT1, PIK3R1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 3.205E-05 | 1.602E-04 | PLA2G1B, KDR, AKT1, PIK3R1, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 4.982E-05 | 2.295E-04 | MMP2, PIM1, AKT1, PIK3R1, NFKB1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.030E-05 | 6.007E-05 | CYP2C9, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 3.528E-05 | 1.715E-04 | AKT1, PIK3R1, TP53, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 2.294E-05 | 1.181E-04 | AKT1, PIK3R1, TP53, NFKB1, PTK2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 4.527E-05 | 2.141E-04 | SRC, MMP2, AKT1, PIK3R1, MMP9 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 7.489E-05 | 3.120E-04 | MMP3, AKT1, PIK3R1, MMP9, NFKB1 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 7.170E-05 | 3.060E-04 | GSK3B, AKT1, PIK3R1, PYGL, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.608E-04 | 5.629E-04 | POLB, SRC, CDK1, PIK3R1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.131E-04 | 4.497E-04 | ABCC1, AKT1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.725E-04 | 5.920E-04 | ABCC1, PIM1, CYP1B1, TP53, MMP9, MET, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.881E-04 | 6.210E-04 | SRC, KDR, AKT1, PIK3R1, MET, IGF1R |
| 09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 1.589E-04 | 5.629E-04 | CAMK2B, GSK3B, MAOA, AKT1, DRD4 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 1.832E-04 | 6.167E-04 | GSK3B, AKT1, PIK3R1, TP53, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 2.327E-04 | 7.143E-04 | LMNA, AKT1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 7.085E-05 | 3.060E-04 | ALK, AKT1, PIK3R1, TP53 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 5.502E-04 | 1.632E-03 | POLB, GSK3B, AKT1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 5.285E-05 | 2.371E-04 | GSK3B, AKT1, PIK3R1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 1.057E-04 | 4.301E-04 | GSK3B, AKT1, PIK3R1, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.349E-04 | 5.133E-04 | AKT1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 1.349E-04 | 5.133E-04 | AKT1, PIK3R1, MET, HIF1A |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.516E-04 | 5.574E-04 | CXCR1, SRC, MET, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 6.147E-04 | 1.763E-03 | CDK1, AKT1, PIK3R1, IGF1R |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 6.147E-04 | 1.763E-03 | CAMK2B, SRC, ALOX12, PIK3R1 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.995E-04 | 6.349E-04 | AKT1, PIK3R1, TP53, NFKB1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.849E-05 | 9.807E-05 | MAOA, CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 1.995E-04 | 6.349E-04 | GSK3B, AKT1, PIK3R1, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 7.685E-04 | 2.169E-03 | GSK3B, AKT1, PIK3R1, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 1.434E-03 | 3.861E-03 | CAMK2B, AR, CDK1, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 1.230E-03 | 3.364E-03 | ALOX5, AKT1, PIK3R1, NFKB1 |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 3.623E-03 | 8.569E-03 | CXCR1, SRC, KDR, MET, IGF1R |
| 09150 Organismal Systems | 09151 Immune system | hsa04670 | Leukocyte transendothelial migration | 1.230E-03 | 3.364E-03 | MMP2, PIK3R1, MMP9, PTK2 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 2.424E-03 | 6.059E-03 | GSK3B, AKT1, PIK3R1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04310 | Wnt signaling pathway | 2.424E-03 | 6.059E-03 | CAMK2B, GSK3B, CSNK2A1, TP53 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04910 | Insulin signaling pathway | 2.243E-03 | 5.773E-03 | GSK3B, AKT1, PIK3R1, PYGL |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 3.025E-03 | 7.353E-03 | GSK3B, AKT1, PIK3R1, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 3.558E-03 | 8.530E-03 | PIM1, AKT1, STAT6, PIK3R1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 2.103E-04 | 6.573E-04 | CSNK2A1, SRC, MET, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 2.576E-04 | 7.774E-04 | SRC, PIK3R1, MET, PTK2 |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 2.078E-03 | 5.428E-03 | AKT1, PIK3R1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 1.726E-03 | 4.577E-03 | AKT1, PIK3R1, HIF1A |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 2.795E-03 | 6.889E-03 | CA2, CYP3A4, ABCG2 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 3.693E-03 | 8.618E-03 | CA2, CA4 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 1.529E-04 | 5.574E-04 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| NA: NA | HIV infections | NA | AHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | TYR; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; FLT3; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
